Clinical trials: Influenza in Humans
Influenza
A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in a Healthy Pediatric Population in the USA
The purpose of this study is to evaluate the immunogenicity and safety profile of CSL425 (CSL's 2009 H1N1 influenza vaccine) in a healthy pediatric population.
- Trial name
- NCT00958243
- Testing
- CSL's 2009 H1N1 Influenza Vaccine (CSL425)
- Where
- 13 sites in United States
- Volunteers
- 473 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
Safety and Immunogenicity of Flublok Quadrivalent vs IIV4 in Adults 18-49 Years of Age
Randomized, double-blind trial of safety and immunogenicity of Flublok Quadrivalent versus Inactivated Influenza Vaccine (IIV4) in 1350 healthy, medically stable adults 18-49 years of age.
- Trial name
- NCT02290509
- Testing
- Flublok Quadrivalent, Inactivated Influenza Vaccine (IIV4)
- Where
- 10 sites in United States
- Volunteers
- 1,350 people, healthy volunteers welcome
- Sponsor
- Protein Sciences Corporation
Relapsing Multiple Sclerosis
Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Flu Vaccination and Tetanus Booster Injection in Patients With Relapsing Multiple Sclerosis (MS)
This study will evaluate the effect of treatment with fingolimod on the immune response following seasonal influenza vaccination and tetanus booster injection in patients with relapsing MS.
- Trial name
- NCT01199861
- Testing
- Fingolimod, Seasonal influenza vaccine, Tetanus toxoid vaccine
- Where
- 25 sites in Belgium, Canada and 7 more
- Volunteers
- 138 people
- Sponsor
- Novartis
Healthy
Studies of Pandemic Influenza (H1N1) 2009 Vaccine in Bergen
Haukeland University Hospital has approximately 8000 employees many of whom will be in the front line to receive the pandemic A/H1N1 vaccine. We propose to conduct a safety and immunogenicity study in these subjects
- Trial name
- H1N1VAC (NCT01003288)
- Testing
- Adjuvanted influenza H1N1split virion vaccine
- Where
- Norway
- Volunteers
- 255 people, healthy volunteers welcome
- Sponsor
- University of Bergen
Influenza
Immunogenicity & Safety of GSK's Influenza Vaccine 1557484A Given to Adults Aged ≥18 Years
The purpose of this Phase 3, observer-blind, placebo-controlled, multi-center study is to characterize the immunogenicity \& safety of the investigation vaccination regimen of GSK 1557484A vaccine given to adults aged ≥18 years.
- Trial name
- NCT00616928
- Testing
- Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted
- Where
- 40 sites in United States, Canada
- Volunteers
- 4,561 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Pandemic
A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Pandemic Flu Vaccine in Healthy Adults
The purpose of this clinical trial is to evaluate the safety and immunogenicity of BW-1014. BW-1014 is a nanoemulsion (NE) adjuvanted recombinant Hemagglutinin 5 (rH5) that would protect against pandemic flu.
- Trial name
- IN-NE-rH5 (NCT05397119)
- Testing
- BW-1014: 25 µg rH5 in 20% NE - pipette - IN, BW-1014: 50 µg rH5 in 20% NE - pipette - IN, BW-1014: 100 µg rH5 in 20% NE - pipette - IN
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- BlueWillow Biologics
Influenza
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine, Fluarix/Influsplit Tetra® (2013/2014 Season), in Adults 18 Years of Age and Older
The purpose of this study is to assess, in adults 18 years of age and above, the immunogenicity and reactogenicity of the seasonal influenza vaccine, Fluarix/Influsplit Tetra containing the four influenza strains (two A strains…
- Trial name
- NCT01878812
- Testing
- Fluarix/Influsplit Tetra® (2013-2014 season)
- Where
- 4 sites in Germany
- Volunteers
- 117 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV, Cancer
Immunogenicity of Fluzone HD,A High Dose Influenza Vaccine, In Children With Cancer or HIV
This is an open label-study of Fluzone HD, a high-dose form of trivalent, inactivated influenza vaccine (TIV), vs. Fluzone, a standard-dose form of TIV.
- Trial name
- NCT01205581
- Testing
- Fluzone High Dose Vaccine, Fluzone Standard Dose Vaccine
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- St. Jude Children's Research Hospital
Influenza, Swine-origin A/H1N1 Influenza
A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Children Aged 6 Months to 9 Years
The purpose of the study is to evaluate different doses of the Influenza A/H1N1 pandemic vaccine in toddlers and children. Primary Objectives: To describe the immunogenicity of the candidate vaccines after each injection.
- Trial name
- NCT00952419
- Testing
- Monovalent Subvirion A/H1N1 Influenza vaccine
- Where
- 20 sites in United States
- Volunteers
- 474 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza, Influenza, Human
Revaccination With Influenza Vaccine GSK1247446A
The protocol is designed to demonstrate the safety of influenza vaccine GSK1247446A after revaccination.
- Trial name
- NCT00545025
- Testing
- Influenza Vaccine GSK1247446A, Fluarix™
- Where
- Belgium
- Volunteers
- 243 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Safety and Immunogenicity of Fluzone® Vaccine in Children Who Received 2 Doses of the 2005-2006 Fluzone Formulation.
To compare the groups with respect to influenza immune responses following Dose 1 of Fluzone vaccine (2006-2007 formulation).
- Trial name
- NCT00390884
- Testing
- Influenza Virus Vaccine, Fluzone®
- Where
- 5 sites in United States
- Volunteers
- 173 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza, Human
A Study on the Safety, Reactogenicity and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults
The purpose of this first-time-in-human (FTiH) study is to assess the safety, reactogenicity and immunogenicity of GlaxoSmithKline's (GSK) messenger RNA (mRNA)-based monovalent vaccine (GSK4382276A) candidate against influenza in…
- Trial name
- NCT05446740
- Testing
- GSK4382276A Dose level 1, GSK4382276A Dose level 2, GSK4382276A Dose level 3
- Where
- 7 sites in Belgium, Canada and 1 more
- Volunteers
- 324 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) - Year 1, 2009
This study will compare influenza vaccine responses in monozygotic and dizygotic twins.
- Trial name
- NCT01987349
- Testing
- Fluzone® (intramuscular), FluMist® (intranasal)
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Stanford University
Influenza
Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Patients With Influenza at High Risk of Influenza Complications
The primary objective of this study is to evaluate the efficacy of a single, oral dose of baloxavir marboxil compared with placebo by measuring the time to improvement of influenza symptoms in patients with influenza presenting…
- Trial name
- CAPSTONE 2 (NCT02949011)
- Testing
- Baloxavir Marboxil, Oseltamivir
- Volunteers
- 2,184 people
- Sponsor
- Shionogi
Influenza
Phase 3 Trial of Serbian Seasonal Influenza Vaccine
A Phase 3, double-blind, randomized, placebo-controlled trial of a seasonal, trivalent, split, inactivated influenza vaccine produced by InstituteTorlak.
- Trial name
- Torlak-300 (NCT02935192)
- Testing
- Vaccine
- Where
- 6 sites in Serbia
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Institute of Virology, Vaccines and Sera, Torlak
Influenza
Comparison of the Safety of Flublok® Versus Licensed IIV in Healthy, Medically Stable Adults ≥ 50 Years of Age
The hypothesis for this trial is that the incidence of a pre-defined composite of common systemic hypersensitivity adverse events for Flublok recipients is non-inferior to that reported for licensed IIV recipients.
- Trial name
- NCT01825200
- Testing
- Flublok, Afluria
- Where
- 14 sites in United States
- Volunteers
- 2,640 people, healthy volunteers welcome
- Sponsor
- Protein Sciences Corporation
Influenza Infection
Phase 1/2 Study of TAK-850 Intramuscular Injection in Healthy Pediatric Participants
The purpose of this study is to evaluate the safety and immunogenicity of an intramuscular injection of TAK-850 in healthy pediatric Japanese participants.
- Trial name
- NCT02367885
- Testing
- TAK-850 0.5 mL injection, TAK-850 0.25 mL injection
- Where
- 2 sites in Japan
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- Takeda
Influenza, Healthy
Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2017-2018 Season
This prospective annual release study is designed to evaluate the safety of 1 new influenza virus vaccine strain to be included in FluMist Quadrivalent for the 2017-2018 influenza season.
- Trial name
- FluMist (NCT03158038)
- Testing
- Monovalent Influenza Vaccine
- Where
- 2 sites in United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza Vaccines
A Randomized Study to Compare the Safety and Immunogenicity of Fluviral® Made With New Versus Aged Bulk
Vaccination is currently the most effective means of controlling influenza and preventing its complications and mortality in persons at risk.
- Trial name
- NCT00586469
- Testing
- Fluviral
- Where
- 8 sites in Canada
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pandemic, Avian Influenza
Immunogenicity, Safety and Tolerability of Prepandemic Influenza and Seasonal Influenza Vaccine in Adult Subjects
This study evaluates the immunogenicity, safety and tolerability of an H5N1 vaccine with a seasonal trivalent influenza vaccine, containing the strains recommended by WHO for the 2007 influenza season in the Southern Hemisphere.
- Trial name
- NCT00481065
- Testing
- MF59-eH5N1, eTIV_a, MF59-eH5N1 + eTIV_a
- Where
- Colombia
- Volunteers
- 405 people, healthy volunteers welcome
- Sponsor
- Novartis